STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows
The microbiome industry is on the cusp of a turning point.
Seres Therapeutics, one of the biggest companies in the field, is set to unveil results from a pivotal clinical trial for its potential fecal matter transplant drug this summer. Two other major players, Rebiotix and Finch Therapeutics, could announce trial results for similar therapies around the same time.
Continue to STAT Plus to read the full story…
